-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Reiterates Outperform on Nuvation Bio, Maintains $20 Price Target

Benzinga·05/05/2026 15:36:50
Listen to the news
RBC Capital analyst Leonid Timashev reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $20 price target.